Back to Search Start Over

Data from Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer

Authors :
David T. Ting
Benjamin D. Greenbaum
Peter J. Park
Kathleen H. Burns
David R. Walt
Shelley L. Berger
Theodore S. Hong
Martin J. Aryee
Miguel N. Rivera
Vikram Deshpande
Ryan B. Corcoran
David P. Ryan
Jennifer Y. Wo
Lipika Goyal
Jeffrey W. Clark
Lawrence S. Blaszkowsky
Jill N. Allen
Hui Zheng
Yasmeen Senussi
Padric M. Garden
Limor Cohen
Vishal Thapar
Matteo Ligorio
Kshitij S. Arora
Niyati Desai
Linda T. Nieman
Michael J. Raabe
Jasmin Joseph-Chazan
Chenyue Lu
Eric C. Tai
Kevin D. Vo
Emily E. Van Seventer
Richard Y. Ebright
Nova Xu
Antuan V. Tran
Stefanie Gerstberger
Annamaria Szabolcs
Charly R. Good
Katherine A. Alexander
Connie Wu
Martin S. Taylor
Christopher Jaicks
Katherine H. Xu
Chong Chu
Anupriya S. Kulkarni
Eunae You
Alexander Solovyov
Aparna R. Parikh
Mihir Rajurkar
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Altered RNA expression of repetitive sequences and retrotransposition are frequently seen in colorectal cancer, implicating a functional importance of repeat activity in cancer progression. We show the nucleoside reverse transcriptase inhibitor 3TC targets activities of these repeat elements in colorectal cancer preclinical models with a preferential effect in p53-mutant cell lines linked with direct binding of p53 to repeat elements. We translate these findings to a human phase II trial of single-agent 3TC treatment in metastatic colorectal cancer with demonstration of clinical benefit in 9 of 32 patients. Analysis of 3TC effects on colorectal cancer tumorspheres demonstrates accumulation of immunogenic RNA:DNA hybrids linked with induction of interferon response genes and DNA damage response. Epigenetic and DNA-damaging agents induce repeat RNAs and have enhanced cytotoxicity with 3TC. These findings identify a vulnerability in colorectal cancer by targeting the viral mimicry of repeat elements.Significance:Colorectal cancers express abundant repeat elements that have a viral-like life cycle that can be therapeutically targeted with nucleoside reverse transcriptase inhibitors (NRTI) commonly used for viral diseases. NRTIs induce DNA damage and interferon response that provide a new anticancer therapeutic strategy.This article is highlighted in the In This Issue feature, p. 1397

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....872fbbb37783ee4cbd8e559e5d98142a